My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
About Us
Plans & Pricing

Moderna (MRNA) Receives a Hold from Needham

Needham analyst Joseph Stringer maintained a Hold rating on Moderna (MRNAResearch Report) today. The company’s shares closed last Wednesday at $434.46, close to its 52-week high of $497.49.

According to, Stringer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.1% and a 29.4% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Lexicon Pharmaceuticals, and Phathom Pharmaceuticals.

Moderna has an analyst consensus of Hold, with a price target consensus of $328.00, representing a -23.3% downside. In a report issued on September 7, Morgan Stanley also maintained a Hold rating on the stock with a $337.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $497.49 and a one-year low of $63.64. Currently, Moderna has an average volume of 17.51M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Read More on MRNA: